TherapeuticsMD, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
TherapeuticsMD reported Q2 2026 net income of $164K (down 70% YoY from $545K), with license revenue of $869K (down 9% from $952K in Q2 2025). Operating expenses rose 2.3% to $1.7M due to higher G&A and patent write-offs. Cash position stands at $9.2M as of June 30, 2026. The company continues evaluating strategic alternatives including acquisition, merger, asset sale, or other business combinations, with no timetable or commitment announced.
Why this rating
Sharp profitability decline (-70% YoY) in a $9M market-cap royalty company; exploration of strategic alternatives signals distress. Material relative to company size and business model sustainability risk.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.